The efficacy and safety of FOLFOX therapy for advanced esophageal squamous cell carcinoma

The efficacy and safety of FOLFOX therapy for advanced esophageal squamous cell carcinoma

Abstract Cisplatin-based chemotherapy is the standard advanced esophageal squamous cell carcinoma (ESCC) treatment. However, the 5-fluorouracil plus L-leucovorin and oxaliplatin (FOLFOX) regimen is available in Japan as an alternative to cisplatin-based chemotherapy, but its efficacy and safety rema...

Full description

Saved in:
Bibliographic Details
Main Authors: Kazuhiro Shiraishi, Mao Okada, Shun Yamamoto, Yuki Matsubara, Toshiki Masuishi, Keitaro Shimozaki, Yoshiyuki Yamamoto, Suguru Hirose, Keiji Sugiyama, Mitsuhiro Furuta, Nozomu Machida, Naoki Takahashi, Takako Yoshii, Yosuke Kito, Takao Tsuzuki, Shogen Boku, Kenji Tsuchihashi, Akinori Sugaya, Toshizo Takayama, Azusa Komori, Seiichiro Mitani, Toshihiko Matsumoto, Takashi Nishimura, Kenro Hirata
Format: Article
Language:English
Published: Nature Portfolio 2025-03-01
Series:Scientific Reports
Subjects:
Esophageal cancer
Chemotherapy
FOLFOX
First-line
Later-line
Online Access:https://doi.org/10.1038/s41598-025-92657-7
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Cisplatin-based chemotherapy is the standard advanced esophageal squamous cell carcinoma (ESCC) treatment. However, the 5-fluorouracil plus L-leucovorin and oxaliplatin (FOLFOX) regimen is available in Japan as an alternative to cisplatin-based chemotherapy, but its efficacy and safety remain unclear. Hence, we aimed to evaluate patients with advanced ESCC who received FOLFOX therapy retrospectively. Patients with advanced ESCC who received FOLFOX therapy at 18 institutions between April 2019 and October 2020 were included. Fifty-two patients received first-line FOLFOX treatment, while 39 received later-line FOLFOX treatment. The median progression-free survival, median overall survival, and objective response rate were 3.8 months (95% confidence interval [CI]: 3.0–5.0), 13.9 months (95% CI: 10.3–17.9 months), and 35% in the first-line group and 2.4 months (95% CI: 2.1–3.8 months), 7.2 months (95% CI: 5.3–9.8 months), and 4% in the later-line group, respectively. The most frequent grade 3 or 4 adverse events were neutropenia (23%) and anemia (12%) in the first-line group and neutropenia (18%), anorexia (13%), anemia (10%), and nausea (10%) in the later-line group. First-line FOLFOX treatment is suitable for patients with advanced ESCC. However, FOLFOX has shown limited efficacy as a later-line treatment.
ISSN:2045-2322

Similar Items